<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="correction"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12634591</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1727580</article-id><article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction: Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Guan</surname><given-names>Haixia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Xixuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Mengyan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Shao</surname><given-names>Jinhuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Mengchi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Jialei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jin</surname><given-names>Yahui</given-names></name><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhu</surname><given-names>Jinglin</given-names></name><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1443085/overview"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zheng</surname><given-names>Chunli</given-names></name><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/760579/overview"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role></contrib></contrib-group><aff id="aff1"><institution>Yan&#x02019;an Medical College, Yan&#x02019;an University</institution>, <city>Yan&#x02019;an</city>, <state>Shaanxi</state>,&#x000a0;<country country="cn">China</country></aff><author-notes><corresp id="c001"><label>*</label>Correspondence: Chunli Zheng, <email xlink:href="mailto:chunlizheng@126.com">chunlizheng@126.com</email>; Jinglin Zhu, <email xlink:href="mailto:zhujinglin27@163.com">zhujinglin27@163.com</email>; Yahui Jin, <email xlink:href="mailto:sxxajyh@126.com">sxxajyh@126.com</email></corresp></author-notes><pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-11-07"><day>07</day><month>11</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="collection"><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>07</day><month>11</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>16</volume><elocation-id>1727580</elocation-id><history><date date-type="received"><day>18</day><month>10</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>10</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Zhang, Guan, Feng, Liu, Shao, Liu, He, Jin, Zhu and Zheng.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhang, Guan, Feng, Liu, Shao, Liu, He, Jin, Zhu and Zheng</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2025-11-07">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><related-article related-article-type="corrected-article" ext-link-type="doi" id="RA1" xlink:href="10.3389/fimmu.2025.1616414" journal-id="Front Immunol" journal-id-type="nlm-ta">A Correction on
<article-title>Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival</article-title> By&#x000a0;Zhang Y, Guan H, Feng X, Liu M, Shao J, Liu M, He J, Jin Y, Zhu J and Zheng C (2025)&#x000a0;<italic toggle="yes">Front. Immunol.</italic>&#x000a0;16:1616414. doi:&#x000a0;<object-id>10.3389/fimmu.2025.1616414</object-id>
</related-article><kwd-group><kwd>colorectal cancer immunotherapy</kwd><kwd>immune checkpoint inhibitors</kwd><kwd>cancer vaccines</kwd><kwd>adoptive cell therapy</kwd><kwd>matrix-depletion therapy</kwd></kwd-group><counts><fig-count count="0"/><table-count count="1"/><equation-count count="0"/><ref-count count="0"/><page-count count="2"/><word-count count="207"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cancer Immunity and Immunotherapy</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>There was a mistake in <xref rid="T7" ref-type="table"><bold>Table&#x000a0;7</bold></xref> as published. The phases corresponding to NCT06751966 and NCT06751914 were omitted. The corrected <xref rid="T7" ref-type="table"><bold>Table&#x000a0;7</bold></xref> appears below.</p><table-wrap position="float" id="T7"><label>Table&#x000a0;7</label><caption><p>Clinical trials based on neoantigen vaccines for the treatment of colorectal cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">ClinicalTrials.Gov identifier</th><th valign="middle" align="center" rowspan="1" colspan="1">Combinatorial agent(s)</th><th valign="middle" align="center" rowspan="1" colspan="1">Phase</th><th valign="middle" align="center" rowspan="1" colspan="1">Primary endpoint</th><th valign="middle" align="center" rowspan="1" colspan="1">Status</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT03948763</td><td valign="middle" align="center" rowspan="1" colspan="1">Pembrolizumab</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1</td><td valign="middle" align="center" rowspan="1" colspan="1">DLTs</td><td valign="middle" align="center" rowspan="1" colspan="1">Terminated</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT06195384</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1</td><td valign="middle" align="center" rowspan="1" colspan="1">Safety</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT06496373</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1</td><td valign="middle" align="center" rowspan="1" colspan="1">Reaction of antigen-specific T cells</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT05359354</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Not Applicable</td><td valign="middle" align="center" rowspan="1" colspan="1">MTD,DLTs</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT05916248</td><td valign="middle" align="center" rowspan="1" colspan="1">Pembrolizumab</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1</td><td valign="middle" align="center" rowspan="1" colspan="1">MTD,DLTs,ORR,DCR</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT05940181</td><td valign="middle" align="center" rowspan="1" colspan="1">Sintilimab</td><td valign="middle" align="center" rowspan="1" colspan="1">Interventional</td><td valign="middle" align="center" rowspan="1" colspan="1">MTD,DLTs,Safety</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT06497010</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1</td><td valign="middle" align="center" rowspan="1" colspan="1">RP2D</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT03639714</td><td valign="middle" align="center" rowspan="1" colspan="1">Nivolumab;Ipilimumab</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1,2</td><td valign="middle" align="center" rowspan="1" colspan="1">TEAEs,DLTs,ORR, RP2D</td><td valign="middle" align="center" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT06751966</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Not Applicable</td><td valign="middle" align="center" rowspan="1" colspan="1">ORR,DCR,Safety</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT06751914</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Not Applicable</td><td valign="middle" align="center" rowspan="1" colspan="1">ORR,DCR,Safety</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT04147078</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1</td><td valign="middle" align="center" rowspan="1" colspan="1">DFS</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT04117087</td><td valign="middle" align="center" rowspan="1" colspan="1">Nivolumab;Ipilimumab</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1</td><td valign="middle" align="center" rowspan="1" colspan="1">Safety,Fold change in CD8 and CD4 T cells</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT02600949</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1</td><td valign="middle" align="center" rowspan="1" colspan="1">Feasibility,TEAEs</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT03552718</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1</td><td valign="middle" align="center" rowspan="1" colspan="1">Safety,RP2D</td><td valign="middle" align="center" rowspan="1" colspan="1">Active</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT04041310</td><td valign="middle" align="center" rowspan="1" colspan="1">Pembrolizumab</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1,2</td><td valign="middle" align="center" rowspan="1" colspan="1">DLTs,ORR,Safety,<break/>Tolerability</td><td valign="middle" align="center" rowspan="1" colspan="1">Active</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT03953235</td><td valign="middle" align="center" rowspan="1" colspan="1">Nivolumab;Ipilimumab</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase 1,2</td><td valign="middle" align="center" rowspan="1" colspan="1">TEAEs,DLTs,<break/>ORR, RP2D</td><td valign="middle" align="center" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT04912765</td><td valign="middle" align="center" rowspan="1" colspan="1">Nivolumab</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase 2</td><td valign="middle" align="center" rowspan="1" colspan="1">PFS</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT06522919</td><td valign="middle" align="center" rowspan="1" colspan="1">Pembrolizumab</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase 2</td><td valign="middle" align="center" rowspan="1" colspan="1">ORR,PFS</td><td valign="middle" align="center" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCT05141721</td><td valign="middle" align="center" rowspan="1" colspan="1">Atezolizumab;Fluoropyrimidine;Bevacizumab;Ipilimumab</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase 2,3</td><td valign="middle" align="center" rowspan="1" colspan="1">ctDNA,PFS</td><td valign="middle" align="center" rowspan="1" colspan="1">Active</td></tr></tbody></table></table-wrap><p>The original version of this article has been updated.</p></body><back><fn-group><fn id="n1" fn-type="approved-by"><p>Approved by: <ext-link xlink:href="https://loop.frontiersin.org/people/111428" ext-link-type="uri">Frontiers Editorial Office</ext-link>, Frontiers Media SA, Switzerland</p></fn></fn-group><sec sec-type="disclaimer" id="s1"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec></back></article>
